Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis

Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis

AbstractAnti-PD-1/PD-L1 antibodies are widely used in anti-cancer therapy. While they have improved cancer prognoses, immune-related adverse events, which can cause acute kidney injury (AKI), cannot be ignored. The purpose of this retrospective cohort study was to assess the incidence, risk factors,...

Full description

Bibliographic Details
Main Authors: Qianqian Lou, Jianguang Gong, Binxian Ye, Rizhen Yu, Shuangshan Bu, Yiwen Li, Bin Zhu, Lina Shao
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Renal Failure
Subjects:
Anti-PD-1/PD-L1 antibodies
acute kidney injury
cancer
risk factors
prognosis
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2023.2238823

Internet

https://www.tandfonline.com/doi/10.1080/0886022X.2023.2238823

Similar Items